About Us

The Brightest Light …

NanoLight® Technologies is a division of Prolume Ltd., formed by Prolume’s founder Dr. Bruce Bryan and a group of excellent co-founders from Prolume® Ltd. namely Byron Ballou PhD; Gene Finely MD; Chris Szent-Gyorgyi PhD; Randall Murphy PhD and Miroslav Trampota.

Nanolight® Technology is a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.

Valuable life science uses for NanoLight®’s technology include high-throughput drug discovery, functional genomics, tumor imaging, replacement of radioisotopes, and molecular diagnostics. One particularly exciting application is the ability to use NanoLight®’s reporter systems to “illuminate” gene and molecular function within living cells, allowing pharmaceutical companies a revolutionary method to study drug activity. A second opportunity is to broadly supply researchers who are increasingly moving away from radioactive reagents toward light-based reporter systems and instruments. NanoLight® Technologies is poised to capitalize on both of these accelerating market trends.

NanoLight’s competitive advantage 

Our advantage is based on three crucial proprietary positions:

  • Access to the novel bioluminescent and fluorescent protein molecules.
  • World’s lowest-cost production technology for coelenterazine (NanoFuel™), necessary for light emission.
  • World’s largest collection of expression libraries from marine bioluminescent organisms.These proprietary technologies, which NanoLight has already developed or protected by patent filings & trade secrets, permit the company to grow into the dominant supplier of proprietary bioluminescent reagents and reporter systems to the life science markets. NanoLight® can immediately provide partners access to:
    • Novel GFP genes isolated from Ptilosarcus gurneyi and Renilla Mulleri with distinctive properties including a novel chromophore sequence that differs in 3 of 6 residues from the Aequorea GFP.
    • Novel marine luciferases cloned from Renilla Mulleri, Pleuromama sp., and Gaussia sp., the latter appears to be brighter than existing Renilla or Firefly systems in mammalian cells.
    • Pending patents on the novel use of bioluminescent proteins on silicon chips for inexpensive high throughput screening and diagnostic applications.
    • cDNA libraries from over forty (40) different luminescent organisms for further gene discovery patenting, and licensing.
    • Proprietary functional screening methods to identify new bioluminescent genes.

    This enormous genetic resource represents an outstanding opportunity for leading life sciences companies racing to establish advanced high-throughput screening and diagnostic systems.